๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Zhengzhou
Clinical trial register · China

Clinical Trials in Zhengzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 20 Guangzhou 16 Chongqing 13 Hefei 11 Zhengzhou 11
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing20 Guangzhou16 Chongqing13 Hefei11 Zhengzhou11
All 59 locations
Target enrolment
to

Trials with a site in Zhengzhou

11 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Clinical Study of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in the Treatment of Advanced Colorectal Cancer
NCT07653685Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
71
Beijing, Lanzhou, Nanning, Zunyi, Harbin, Zhengzhou, Jingzhou, Wuhan
2026-07
Recruiting
A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies
NCT07113925Advanced Hematologic Malignancies
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
114
Zhengzhou, Nanchang, Shanghai
2025-08-01
Recruiting
A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors
NCT07043751Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
216
Beijing, Dongguan, Guangdong, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha
2025-07-15
Recruiting
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
NCT07003074Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
642
Hefei, Beijing, Lanzhou, Shantou, Harbin, Kaifeng, Puyang, Zhengzhou
2025-06-23
Recruiting
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
NCT06754891Inflammatory Bowel Diseases
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
135
Bengbu, Wuwei, Guangzhou, Huizhou, Harbin, Luoyang, Nanyang, Zhengzhou
2025-01-28
Recruiting
The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
NCT06452706Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
42
Bozhou, Chuzhou, Hefei, Maโ€™anshan, Wuhu, Harbin, Zhengzhou, Wuhan
2024-11-14
Active, closed
A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A
NCT06297655Hemophilia A
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
60
Fuyang, Hefei, Chongqing, Lanzhou, Guangzhou, Nanning, Zhengzhou, Changsha
2024-11-12
Not yet open
A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia
NCT06672263Chronic Myelogenous Leukemia
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
120
Beijing, Nanning, Zhengzhou, Shanghai, Hangzhou
2024-11
Recruiting
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms
NCT06767813Pancreatic Neoplasms
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
80
Zhengzhou, Nanjing, Suzhou, Shanghai, Wenzhou
2024-03-19
Recruiting
Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
NCT06188624Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
150
Chongqing, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Dalian, Shenyang
2024-02-01
Active, closed
Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers
NCT05735496Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
219
Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing, Shenyang, Xi'an
2023-03-09
Rows per page Showing 1–11 of 11
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/zhengzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 11 of those studies with a site in Zhengzhou that also match the filters currently applied.

How many clinical trials are recruiting in Zhengzhou?

7 of the 11 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Zhengzhou), 11 studies
PhaseStudiesRecruitingShare
Phase 16454.5%
Phase 22218.2%
Phase 32118.2%
Phase 1/2109.1%

Most active sponsors

Lead sponsors with the most studies (Zhengzhou)
Lead sponsorStudiesRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.117
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.